Avicanna

Avicanna R&D per Employee

The R&D Spending per Employee of Avicanna (AVCN.TO) as of Nov 21, 2026 is 13,495.84 CAD. In the previous year, R&D Spending per Employee was 9,376.68 CAD — a change of 43.93% (higher).

R&D per Employee

13,495.84CAD

YoY

43.93%

Last updated:

R&D Spending per Employee of Avicanna is 2025 13,495.84 CAD. R&D Spending per Employee of Avicanna was 2024 9,376.68 CAD. It decreases by 43.93% higher compared to the previous year.

The Avicanna R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
24,032.74 CAD
Jan 1, 2019
64,052.63 CAD
Jan 1, 2020
19,803.74 CAD
Jan 1, 2021
16,016.42 CAD
Jan 1, 2022
14,575.68 CAD
Jan 1, 2023
17,403.26 CAD
Jan 1, 2024
9,376.68 CAD
Jan 1, 2025
13,495.84 CAD
The Avicanna R&D per Employee history
YEARR&D per EmployeeYoY
13,495.84CAD+43.93%
9,376.68CAD-46.12%
17,403.26CAD+19.40%
14,575.68CAD-9.00%
16,016.42CAD-19.12%
19,803.74CAD-69.08%
64,052.63CAD+166.52%
24,032.74CAD+1,828.47%
1,246.21CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Avicanna Stock analysis

What does Avicanna do? Avicanna Inc is a Canadian biopharmaceutical company specializing in the research, development, and manufacturing of medical marijuana products. The company was founded in 2016 by its president and CEO Aras Azadian, who has extensive experience in the pharmaceutical and biotechnology industry. The company is based in Toronto, Canada and also operates in Colombia and Switzerland. Avicanna has several subsidiaries, including Santa Marta Golden Hemp, which operates its cultivation business in Colombia. Avicanna's business model is focused on producing medical marijuana products that have better efficacy and tolerability than conventional products. The company uses a specialized process called PhytoVista™ to isolate and extract the active ingredients in plant extracts. Avicanna operates in various sectors, including the manufacturing and marketing of medical marijuana products, research and development of effective medical treatments, and collaboration with healthcare facilities and government agencies in marijuana regulation. The company offers a variety of products, including different types of hemp oil, CBD products, and pharmaceutical products such as Rho PhytoTM and Pura EarthTM. These products all share the common approach of providing patients with better, more effective, and tolerable treatment options. Rho PhytoTM is a patented medical marijuana product by Avicanna, derived from a specific cannabis strain called ACMPR. This product is approved in Canada and available as an oral solution and syringe. Rho PhytoTM is specifically tailored to meet the needs of patients with neurodegenerative diseases and has proven to be effective. Pura EarthTM is a herbal remedy derived from the medical marijuana plant and is intended to be used as an alternative medicine for pain and inflammation. In addition to manufacturing medical marijuana products, the company also conducts intensive research and development to develop medications based on synthetic cannabinoids. These substances have the potential to help patients with various conditions such as multiple sclerosis, epilepsy, and tumor diseases. Avicanna also has partnerships with various healthcare facilities and government agencies to advance the regulation of medical marijuana and ensure the safety and efficacy of these products. In summary, Avicanna is an innovative biopharmaceutical company specializing in the manufacturing and marketing of medical marijuana products. The company serves various areas within the marijuana industry, including the production of medical products, research and development, and regulation of marijuana products. With an extensive product range and a strong research and development department, Avicanna is well positioned to continue growing and developing more innovative products in the coming years. Avicanna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Avicanna stock

R&D Spending per Employee of Avicanna is 13,495.84 CAD in 2025.

R&D Spending per Employee of Avicanna changed from 9,376.68 CAD to 13,495.84 CAD, representing a 43.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Avicanna since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Avicanna historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Avicanna

All Key Metrics — Avicanna